US FDA approves Sanofi's wearable injector form of blood cancer drug…

The FDA has approved Sarclisa Escena, a wearable subcutaneous injector form of Sanofi's blood cancer drug, replacing intravenous infusions for multiple myeloma patients and reducing oncology clinic burden. If you're building oncology clinic software, patient scheduling, or infusion center logistics, your market just shrank—subcutaneous wearables cut clinic visit time from hours to minutes, and systems built around chair time become obsolete. The win here is for companies selling home-based cancer monitoring, nursing support, or safety software that works outside the clinic.